United Therapeutics (Nasdaq: UTHR) is selling a voucher designed to speed up approval for rare pediatric disease treatments to Chicago-based pharmaceutical company AbbVie Inc. for a record $350 million.
The Wall Street Journal reports the Silver Spring-based biotechnology company landed the voucher when it received approval from the Food and Drug Administration for Unituxin, its drug designed to treat neuroblastoma.
Sara Nayeem will participate in the Biotechnology Industry Organization webinar entitled, “Capturing Investor Interest in a Hot Biotech Climate,” on Tuesday, August 18th at 1PM EST. The panel will explore the strong biotech market and answer questions from start-ups seeking funding in their venture.
The biotech market is stronger than ever with more than $5B invested in 2015 so far. With the influx of capital flowing in the biotech pools, the panel will advise startups on what to look for when interviewing investment firms, what due diligence is needed to find appropriate investment partners, and what steps a company should take to ensure that the partnership runs smoothly.
Google Inc. (NASDAQ:GOOG) is a major consumer technology developer and Internet services giant which is involved in an incredibly diverse array of innovative tech fields. The company is best known for its Internet search engine, which processes an average of about 40,000 search queries every second, but in our Companies We Follow series we’ve seen them develop everything from robots with humanoid personalities to medical emergency response drones. We’ve covered Google acquisitions that have pulled the company into the sphere of digital wallet tech as well as patenting activities in the field of autonomous vehicles. It’s clear that the tentacles of the corporate octopus that is Google stretch wide and far away from each other.
Applications for consideration in Relevant Health’s first cohort must be submitted by this Friday, August 21st at 11:59pm Eastern Time.
Complete or submit your application here.
Relevant Health will begin reviewing applications submitted through F6S next week.
Here is the review process schedule:
In the May 15, 2014, edition of the journal Nature, Floyd Romesberg’s chemistry lab at San Diego’s Scripps Research Institute published a paper titled “A Semi-Synthetic Organism with an Expanded Genetic Alphabet.” Romesberg and his colleagues had created a bacterium incorporating chemical building blocks that, as far as anybody knows, have never been part of any earthly life form.
There had been previous claims to “creating life.” Genome pioneer Craig Venter led a team that manufactured a genome for a germ that causes pneumonia in cows, but their effort used the familiar chemical bases of DNA, known by the letters A, G, C, and T. Romesberg’s group, on the other hand, added two additional letters, dubbed X and Y. When the bacteria successfully replicated X and Y in succeeding generations, Romesberg’s lab could claim to have made the first living thing with an expanded genetic code.
The company is just so much better known its medical countermeasures against biological threats like anthrax than for its cancer work, and that’s a problem.
We’ve been covering news of the GlucoTrack non-invasive glucometer for almost a decade now, and finally Integrity Applications, the company behind the device, is moving toward clinical trials potential regulatory approval in the U.S. The Israeli firm already received the CE mark in Europe for the GlucoTrack model DF-F two years ago, and the same device is in the pre-submission documents filed with the FDA.
The GlucoTrack uses an ear lobe clip-on similar to pulse oximeters to spot glucose levels through the skin. The sensor uses three different technologies to estimate blood glucose and sends its readings to a smartphone-like device that displays the numbers and keeps track of previous tests.
With the financial aid of a biotechnology executive whose daughter may need a lung transplant, U.S. researchers have been shattering records in xenotransplantation, or between-species organ transplants.
The researchers say they have kept a pig heart alive in a baboon for 945 days and also reported the longest-ever kidney swap between these species, lasting 136 days. The experiments used organs from pigs “humanized” with the addition of as many as five human genes, a strategy designed to stop organ rejection.
Betamore and Plank Industries, Under Armour CEO Kevin Plank’s private investment arm, are teaming up to showcase Baltimore startups in a new entrepreneurship event.
The Oct. 1 event, called Beta City, is intended to highlight promising Baltimore startups, connect entrepreneurs to venture capitalists and showcase Baltimore as an emerging startup hub. The day will include a pitch session, a VIP event at Plank Industries’ new innovation center and networking opportunities.
Mere months after a major venture capital fundraise, Rockville-based biotech RegenxBio Inc. says it’s ready to go public. UPCOMING EVENTS AUGUST 18, 2015 , 11:45AM Washington Business Journal: Lead Generation Seminar
In an initial regulatory filing Monday with the Securities and Exchange Commission, the company said it would trade on the Nasdaq exchange under the ticker symbol RGNX. It has yet to say how much it plans to raise and set either a price for the stock or date for the initial public offering. Morgan Stanley & Co. LLC (NYSE: MS), BofA Merrill Lynch, Piper Jaffray and Chardan Capital Markets LLC will manage the IPO.
